Revenue from operations for the quarter came in at Rs 251 crore, marking a robust 47% increase compared with the corresponding quarter of the previous financial year.
The company also declared a dividend of Rs 75 per share for the year ended December 31, 2025.
For the full year 2025, Sanofi Consumer reported revenue of Rs 878.4 crore, reflecting 21% growth over the previous year. “The gains were supported by the relaunch of recalled products in the market,” the company said in a regulatory filing.
Profit after tax for the year stood at Rs 240 crore, up 33% year-on-year, supported by disciplined cost management and an improved product mix.
Export performance also saw a sharp uptick on a low base. In Q4, export sales surged 9.3 times year-on-year. For FY25, export sales rose 158% year-on-year, again reflecting the impact of a subdued base.
Commenting on the results, Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, said: “Our domestic business has delivered healthy double-digit growth for two successive quarters, complemented by strong contributions from our export markets. We continue to invest in our brands and remain focused on reinforcing fundamentals and driving operational excellence to unlock the next phase of sustainable growth.”“Our full-year performance reflects the strength of our strategy and the disciplined execution by our teams. By driving sustained growth, deepening portfolio penetration, and accelerating digital transformation, we delivered meaningful outcomes for all our stakeholders. Our strong financial performance this year enables us to reward shareholders with a healthy dividend of Rs 75 per share,” the management added.
Sanofi Consumer Healthcare India is the demerged consumer healthcare division of Sanofi India. The board of Sanofi India approved the demerger on May 10, 2023, separating the Consumer Healthcare business into a new entity, Sanofi Consumer Healthcare India Limited.
The company’s leading consumer healthcare brands include Allegra, DePURA, Avil, and Combiflam.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
